Literature DB >> 25533913

Managing the side effects associated with commonly used treatments for bipolar depression.

David E Kemp1.   

Abstract

BACKGROUND: The most commonly used pharmacologic therapies for bipolar depression are mood stabilizers, atypical antipsychotics, and antidepressants. This paper reviews common side effects associated with these medications and provides recommendations for managing adverse medication effects in clinical practice.
METHODS: Narrative review based on literature searches of Medline and evidence-based treatment guidelines for agents that have been approved by the US Food and Drug Administration and/or are commonly used to treat bipolar depression.
RESULTS: Side effects of bipolar depression pharmacotherapies are common and vary by medication, with weight gain, metabolic dysregulation, sedation/somnolence, and akathisia among those observed most frequently. These adverse events (weight gain and sedation/somnolence, in particular) negatively affect treatment adherence in patients with bipolar disorder. Furthermore, endocrine and metabolic comorbidities, weight gain, and obesity may reduce the likelihood of positive clinical responses to pharmacologic therapies. Clinicians may consider switching patients to bipolar depression medication(s) with a lower propensity for sedation or adverse metabolic effects. Lifestyle modification (e.g., dietary changes, exercise) is an important component in the treatment of weight gain/obesity, dyslipidemia, hypertension, and hyperglycemia; in addition, a wide range of medications are available as therapeutic options for patients in whom non-pharmacologic management strategies are insufficient. The use of adjunctive medication may also reduce treatment-related sedation and somnolence. LIMITATIONS: The selection of relevant studies from the literature search relied primarily on the author's expertise in the area of bipolar depression and knowledge of the issues addressed.
CONCLUSION: Successful treatment of bipolar depression extends beyond managing mood symptoms to also monitoring adverse medication events and managing associated medical disorders.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; Depression; Pharmacotherapy; Side effects

Mesh:

Substances:

Year:  2014        PMID: 25533913     DOI: 10.1016/S0165-0327(14)70007-2

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  17 in total

1.  Identifying clinical net benefit of psychotropic medication use with latent variable techniques: Evidence from Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

Authors:  Natalie Bareis; Juan Lu; Cynthia K Kirkwood; Susan G Kornstein; Elwin Wu; Briana Mezuk
Journal:  J Affect Disord       Date:  2018-05-29       Impact factor: 4.839

2.  Quetiapine-induced hypertriglyceridaemia causing acute pancreatitis.

Authors:  John Mark Franco; Saraschandra Vallabhajosyula; Timothy John Griffin
Journal:  BMJ Case Rep       Date:  2015-05-14

3.  Dosing patterns and medication adherence in bipolar disorder patients treated with lurasidone: a US retrospective claims database analysis.

Authors:  Martha Sajatovic; Daisy Ng-Mak; Caitlyn T Solem; Fang-Ju Lin; Krithika Rajagopalan; Antony Loebel
Journal:  Ther Adv Psychopharmacol       Date:  2016-10-13

Review 4.  An Overview of Links Between Obesity and Mental Health.

Authors:  Christian Avila; Alison C Holloway; Margaret K Hahn; Katherine M Morrison; Maria Restivo; Rebecca Anglin; Valerie H Taylor
Journal:  Curr Obes Rep       Date:  2015-09

Review 5.  Antipsychotic inductors of brain hypothermia and torpor-like states: perspectives of application.

Authors:  Yury S Tarahovsky; Irina S Fadeeva; Natalia P Komelina; Maxim O Khrenov; Nadezhda M Zakharova
Journal:  Psychopharmacology (Berl)       Date:  2016-12-08       Impact factor: 4.530

Review 6.  Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges.

Authors:  Haitham Salem; Caesa Nagpal; Teresa Pigott; Antonio Lucio Teixeira
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 7.  Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape.

Authors:  Kenneth Blum; Marcelo Febo; Rajendra D Badgaiyan; Zsolt Demetrovics; Thomas Simpatico; Claudia Fahlke; Oscar-Berman M; Mona Li; Kristina Dushaj; Mark S Gold
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 8.  Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy.

Authors:  Paula Kopschina Feltes; Janine Doorduin; Hans C Klein; Luis Eduardo Juárez-Orozco; Rudi Ajo Dierckx; Cristina M Moriguchi-Jeckel; Erik Fj de Vries
Journal:  J Psychopharmacol       Date:  2017-06-27       Impact factor: 4.153

9.  Patient preferences for important attributes of bipolar depression treatments: a discrete choice experiment.

Authors:  Daisy Ng-Mak; Jiat-Ling Poon; Laurie Roberts; Leah Kleinman; Dennis A Revicki; Krithika Rajagopalan
Journal:  Patient Prefer Adherence       Date:  2017-12-28       Impact factor: 2.711

10.  Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study.

Authors:  Willie R Earley; Maria V Burgess; Barbara Khan; Ludmyla Rekeda; Trisha Suppes; Mauricio Tohen; Joseph R Calabrese
Journal:  Bipolar Disord       Date:  2019-11-06       Impact factor: 6.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.